Arcutis Biotherapeutics (ARQT) Q2 2024 earnings summary

Executive summary

• Achieved Q2 2024 net product revenues of $30.9 million, up 547% year-over-year and 43% sequentially, driven by strong prescription growth for ZORYVE cream and foam, with launches in psoriasis, seborrheic dermatitis, and atopic dermatitis.

• ZORYVE cream 0.3% generated $17.3 million and foam 0.3% $13.6 million in Q2 2024 revenue, with over 252,000 cream and 98,000 foam prescriptions filled since launch.

• Entered a co-promotion agreement with Kowa Pharmaceuticals to expand into primary care and pediatric markets, with meaningful revenue contribution expected in 2025.

• Completed a $161.7 million public equity offering and received $25 million upfront from a Sato licensing agreement, strengthening liquidity.

• Amended debt agreement extends maturity to 2029, lowers interest rate by 150 basis points, and adds flexibility for repayments and asset purchases.

Financial highlights

• Net product revenues for Q2 2024 were $30.9 million, compared to $4.8 million in Q2 2023 and $21.6 million in Q1 2024.

• Net loss was $52.3 million ($0.42 per share) for Q2 2024, improved from $71.0 million ($1.16 per share) in Q2 2023.

• R&D expenses decreased to $19.3 million from $25.2 million year-over-year; SG&A expenses increased to $58.2 million from $46.0 million.

• Cash, cash equivalents, and marketable securities totaled $363.1 million as of June 30, 2024.

• Net cash used in operating activities was $45.2 million in Q2 2024.

Outlook and guidance

• Sustained revenue growth expected in 2024, driven by prescription demand in psoriasis, seborrheic dermatitis, and atopic dermatitis, with further gross-to-net improvements moderating.

• Kowa co-promotion to drive primary care and pediatric growth, with significant impact anticipated in 2025.

• Management expects continued operating losses as commercialization and development efforts expand, but capital resources are projected to fund operations for at least 12 months.